切换至 "中华医学电子期刊资源库"

中华临床医师杂志(电子版) ›› 2020, Vol. 14 ›› Issue (02) : 105 -109. doi: 10.3877/cma.j.issn.1674-0785.2020.02.006

所属专题: 文献

临床研究

15例Xp11.2易位/TFE3基因融合相关性肾癌的临床病理特点分析
沈棋1,(), 胡帅1, 李峻1, 王静华1, 刘漓波1, 何群1   
  1. 1. 100034 北京大学第一医院泌尿外科,北京大学泌尿外科研究所,国家泌尿、男性生殖系肿瘤研究中心
  • 收稿日期:2020-01-14 出版日期:2020-02-15
  • 通信作者: 沈棋

Renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion: clinicopathological analysis of 15 cases

Qi Shen1,(), Shuai Hu1, Jun Li1, Jinghua Wang1, Libo Liu1, Qun He1   

  1. 1. Department of Urology, Peking University First Hospital; Institute of Urology, Peking University; National Urological Cancer Center, Beijing 100034, China
  • Received:2020-01-14 Published:2020-02-15
  • Corresponding author: Qi Shen
  • About author:
    Corresponding author: Shen Qi, Email:
引用本文:

沈棋, 胡帅, 李峻, 王静华, 刘漓波, 何群. 15例Xp11.2易位/TFE3基因融合相关性肾癌的临床病理特点分析[J/OL]. 中华临床医师杂志(电子版), 2020, 14(02): 105-109.

Qi Shen, Shuai Hu, Jun Li, Jinghua Wang, Libo Liu, Qun He. Renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion: clinicopathological analysis of 15 cases[J/OL]. Chinese Journal of Clinicians(Electronic Edition), 2020, 14(02): 105-109.

目的

探讨Xp11.2易位/TFE3基因融合相关性肾癌的临床病理学特征、诊断要点及鉴别诊断。

方法

回顾性分析15例Xp11.2易位/TFE3基因融合相关性肾癌患者的临床特征、组织学特点、免疫组化及荧光原位杂交,并结合相关文献复习讨论。

结果

15例患者中,男性6例,女性9例,平均(31.3±9.3)岁。12例为体检偶然发现,临床主要症状表现为血尿和腰腹部疼痛。肿瘤直径1.5~15 cm,平均5.4 cm,3例诊断时已发生转移。10例标本大体呈实性,切面灰白多见,其次为杂色、灰褐,5例切面伴囊性变,5例可见出血及坏死区域。镜下观察可见肿瘤由嗜酸性细胞或透明细胞构成的乳头状、巢状及腺泡状结构,肿瘤细胞界限清楚,核仁较明显,间质主要为纤细的纤维血管间隔,4例可以见到砂砾体。免疫组织化学结果显示肿瘤细胞均弥漫表达TFE3、PAX-8及CD10,不同程度表达AE1/AE3、Vimentin、HMB45及AMACR/P504S,CAIX、CK7、CD117均阴性表达。所有病例TFE3荧光原位杂交检测存在TFE3信号分离。

结论

Xp11.2易位/TFE3基因融合相关性肾癌是一种罕见的肾细胞癌类型,女性高发于男性,其诊断主要依靠组织病理学、免疫组织化学标记TFE3荧光原位杂交来确诊。

Objective

To investigate the clinicopathological features, diagnosis, and differential diagnosis of Xp11.2 translocation/ TFE3 fusion-related renal cell carcinoma.

Methods

A total of 15 cases of Xp11.2 translocation/ TFE3 fusion-related renal cell carcinoma were analyzed with regard to clinical data, histology, immunohistochemistry, and fluorescence in situ hybridization (FISH) findings.

Results

Six patients were male and the other nine were female. Their mean age was (31.3±9.3) years. The main clinical manifestations were hematuria and waist pain. Mean tumor diameter was 5.4 cm (range, 1.5-15 cm). Ten cases of the gross specimens were solid and had a grey, yellow, or tan cut surface. Five cases of the gross specimens were cystic-solid. Microscopic examination showed that the distinctive histological pattern was papillary, nested, and acini-like structure. The tumor cells had a clear boundary, eosinophilic or clear cytoplasm, and prominent nucleoli. And in 4 cases, psammoma bodies were observed. Immunohistochemistry results showed that TFE3, PAX-8, and CD10 were diffusely expressed in all cases. The expression of AE1/AE3, vimentin, HMB45, and AMACR/P504S varied among cases. The expression of CAIX, CK7, and CD117 was negative in all cases. All cases showed positive results in the FISH assay.

Conclusion

Xp11.2 translocation/TFE3 gene fusion-associated renal cell carcinoma is a rare renal malignancy and mainly occurs in females. Its diagnosis relies mainly on histopathology, immunohistochemistry, and FISH assay.

图1 Xp11.2易位/TFE3基因融合相关性肾癌 肿瘤由嗜酸性细胞或透明细胞构成的乳头状、巢状及腺泡状结构,肿瘤细胞界限较清楚,胞浆丰富,嗜酸或透明,部分病例可见到砂砾体;图a、b为HE染色(×100);图c、d为HE染色(×200)
表1 15例Xp11.2易位/TFE3基因融合相关性肾癌免疫组化表达情况
图2 Xp11.2易位/TFE3基因融合相关性肾癌免疫组织化学染色(×200)
图3 Xp11.2易位/TFE3基因融合相关性肾癌TFE3荧光原位杂交检测 图a为女性病例,一个正常的融合信号和一对异常的红绿分离信号;图b为男性病例,一对异常的红绿分离信号
[1]
Ross H, Argani P. Xp11 translocation renal cell carcinoma [J]. Pathology, 2010, 42(4): 369-273.
[2]
Kmetec A, Jeruc J. Xp11. 2 translocation renal carcinoma in young adults; recently classified distinct subtype [J]. Radiol Oncol, 2014, 48(2): 197-202.
[3]
Komai Y, Fujiwara M, Fujii Y, et al. Adult Xp11 translocation renal cell carcinoma diagnosed by cytogenetics and immunohistochemistry [J]. Clin Cancer Res, 2009, 15(4): 1170-1176.
[4]
Klatte T, Streubel B, Wrba F, et al. Renal cell carcinoma associated with transcription factor E3 expression and Xp11.2 translocation: incidence, characteristics, and prognosis [J]. Am J Clin Pathol, 2012, 137(5): 761-768.
[5]
Gong P, Zhuang Q, Wang K, et al. Adult-onset renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion: 3 case reports and review of literature [J]. Medicine (Baltimore), 2018, 97(24): e1123.
[6]
Yang B, Duan H, Cao W, et al. Xp11 translocation renal cell carcinoma and clear cell renal cell carcinoma with TFE3 strong positive immunostaining: morphology immunohistochemistry, and FISH analysis [J]. Mod Pathol, 2019, 32(10): 1521-1535.
[7]
Argani P, MiT family translocation renal cell carcinoma [J]. Semin Diagn Pathol, 2015, 32(2): 103-113.
[8]
Qu Y, Gu C, Wang H, et al. Diagnosis of adults Xp11.2 translocation renal cell carcinoma by immunohistochemistry and FISH assays: clinicopathological data from ethnic Chinese population [J]. Sci Rep, 2016, 6: 21677
[9]
Argani P, Lal P, Hutchinson B, et al. Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions: a sensitive and specific immunohistochemical assay [J]. Am J Surg Pathol, 2003, 27(6): 750-761.
[10]
Mosquera JM, Dal Cin P, Mertz KD, et al. Validation of a TFE3 break-apart FISH assay in Xp11.2 translocation renal cell carcinomas [J]. Diagn Mol Pathol, 2011, 20(3): 129-137.
[11]
Ross H, Martignoni G, Argani P. Renal cell carcinoma with clear cell and papillary features [J]. Arch Pathol Lab Med, 2012, 136(4): 391-399.
[1] 张妍, 原韶玲, 史泽洪, 郭馨阳, 牛菁华. 小肾肿瘤超声漏诊原因分析新思路[J/OL]. 中华医学超声杂志(电子版), 2024, 21(05): 500-504.
[2] 赵阳, 肖迎聪, 巨艳, 党晓智, 蔡林利, 薛文欣, 李洋, 肖瑶, 郭妤绮, 宋宏萍. 自动乳腺超声联合免疫组化早期预测乳腺癌新辅助化疗病理完全缓解的临床价值[J/OL]. 中华医学超声杂志(电子版), 2024, 21(04): 361-369.
[3] 武壮壮, 张晓娟, 史泽洪, 史瑶, 原韶玲. 超声联合乳腺X线摄影及PR、Her-2预测高级别与中低级别乳腺导管原位癌的价值[J/OL]. 中华医学超声杂志(电子版), 2023, 20(06): 631-635.
[4] 贺媛媛, 李佳, 杨红. 宫颈中肾腺癌1例并文献复习[J/OL]. 中华妇幼临床医学杂志(电子版), 2024, 20(01): 97-104.
[5] 陈怡芳, 黄晓卉. 肝细胞癌中对氧磷酶2的表达及临床意义[J/OL]. 中华普通外科学文献(电子版), 2024, 18(03): 186-191.
[6] 刘政宏, 王凤力, 吉亚君, 高佳. 胃癌中ELK3蛋白的表达与临床病理特征和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(02): 155-159.
[7] 谢汶歆, 马乐, 刘晔, 曹晓明, 张万春. 前列腺特异性膜抗原PET/CT在肾癌诊疗中的应用价值[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(05): 514-519.
[8] 张超, 过菲, 王富博, 叶宸, 杨悦, 杨波. 腹腔镜肾部分切除术:肾癌合并肾静脉癌栓的新选择[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(03): 219-224.
[9] 张子旭, 郑俊炯, 罗云, 林天歆. 腹腔镜肾部分切除术离体猪肾培训模型的构建[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(03): 277-283.
[10] 邓永豪, 曹嘉正. 长链非编码RNA与肾癌的关系及其在肾癌中的临床应用[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(03): 289-293.
[11] 赵佳晖, 王永兴, 彭涛, 李明川, 魏德超, 韩毅力, 侯铸, 姜永光, 罗勇. 后腹腔镜根治性肾切除手术时间延长和术中出血量增多的影响因素分析[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2023, 17(06): 575-580.
[12] 李静波, 朱嘉宁, 宋禄达, 罗渝昆, 李秋洋. 多模态超声成像技术在肾肿瘤诊断中的应用进展[J/OL]. 中华肾病研究电子杂志, 2023, 12(06): 349-353.
[13] 谭瑞义. 小细胞骨肉瘤诊断及治疗研究现状与进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(08): 781-784.
[14] 岳瑞雪, 孔令欣, 郝鑫, 杨进强, 韩猛, 崔国忠, 王建军, 张志生, 孔凡庭, 张维, 何文博, 李现桥, 周新平, 徐东宏, 胡崇珠. 乳腺癌HER2蛋白表达水平预测新辅助治疗疗效的真实世界研究[J/OL]. 中华临床医师杂志(电子版), 2023, 17(07): 765-770.
[15] 沈莹莹, 李伟, 李飞, 易翠兴, 袁思敏. 综合多个遗传学技术鉴别诊断尿道下裂患儿罕见染色体结构重排[J/OL]. 中华诊断学电子杂志, 2024, 12(02): 107-111.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?